For the Quarter Ending September 2025
North America
• In United States, the Lamivudine Price Index experienced upward pressure in Q3 2025, driven by rising production costs.
• Lamivudine production costs rose due to a 3.0% CPI increase in September 2025 and a 2.6% PPI increase in August 2025.
• The Lamivudine Price Forecast indicates continued upward pressure, influenced by anticipated rising operational and labor costs.
• Lamivudine demand outlook strengthened, supported by robust US pharmaceutical market sentiment and surging drug approvals in Q3 2025.
• A low unemployment rate of 4.3% in September 2025 supported Lamivudine demand by improving patient access to healthcare.
• US manufacturing inventories tightened in Q3 2025, with growth outpacing new orders, signaling potential slowing turns.
• Henry Hub natural gas spot prices showed an upward trend towards Q3 2025 end, impacting general manufacturing input costs.
• Trade volumes shifted in Q3 2025 due to accelerated imports ahead of new tariff deadlines, influencing supply chains.
Why did the price of Lamivudine change in September 2025 in North America?
• Rising input prices for key manufacturing materials, including natural gas, increased production costs in Q3 2025.
• A 3.0% CPI increase in September 2025 and a 2.6% PPI increase in August 2025 elevated overall operational expenses.
• Strengthened US pharmaceutical market sentiment and surging drug approvals boosted demand for essential medications.
APAC
• In China, the Lamivudine Price Index fell quarter-over-quarter, influenced by declining producer prices in September 2025.
• Lamivudine production costs decreased due to a 2.3% year-over-year fall in Producer Price Index during September 2025.
• Demand for Lamivudine faced headwinds from a contracting Manufacturing Index in September 2025.
• Robust pharmaceutical market growth in 2025 supported Lamivudine demand despite broader economic softness.
• Stable crude oil and natural gas prices in Q3 2025 contributed to consistent Lamivudine feedstock costs.
• China's industrial production expanded by 6.5% year-over-year in September 2025, supporting overall economic activity.
• Softening domestic consumption, with 3.0% retail sales growth and 5.2% unemployment in September 2025, pressured demand.
• Deflationary Consumer Price Index at -0.3% in September 2025 and persistent chemical overcapacity maintained downward price pressure.
Why did the price of Lamivudine change in September 2025 in APAC?
• Declining producer prices, down 2.3% year-over-year in September 2025, reduced manufacturing costs.
• Weak consumer confidence and 5.2% unemployment in September 2025 dampened Lamivudine demand.
• Persistent chemical industry overcapacity in Q3 2025 exerted downward pressure on prices.
Europe
• In Germany, the Lamivudine Price Index remained stable in Q3 2025, influenced by mixed cost pressures and firm pharmaceutical demand.
• Lamivudine production costs faced persistent high operating expenses in Q3 2025, despite basic chemical producer prices inching down in July.
• Demand for Lamivudine was supported by firming German pharmaceutical sector output in Q3 2025 and a 0.2% rise in retail sales.
• The Manufacturing Index was contracting in Q3 2025, and industrial production declined 1.0% in September 2025, indicating supply challenges.
• High electricity costs continued to erode industrial competitiveness throughout Q3 2025, impacting Lamivudine manufacturing.
• German chemical industry's international sales weakened significantly in Q3 2025, affected by erratic US trade policies.
• The CPI increased 2.4% in September 2025, suggesting rising general costs for Lamivudine production and distribution.
• Government initiatives to stabilize industrial electricity prices, announced for late 2025, may influence future Lamivudine costs.
• Unemployment remained stable at 6.3% in September 2025, potentially impacting healthcare funding and patient access.
Why did the price of Lamivudine change in September 2025 in Europe?
• Producer prices decreased -1.7% in September 2025, due to lower energy costs.
• Consumer Price Index increased 2.4% in September 2025, indicating rising general operational expenses.
• Industrial production declined 1.0% in September 2025, suggesting potential supply chain constraints.